人民财讯12月23日电，众生药业（002317）12月23日公告，公司近日收到国家药监局核准签发的盐酸氨 溴索口服溶液《药品注册证书》。盐酸氨溴索口服溶液适用于急、慢性支气管炎引起的痰液黏稠、咳痰 困难，有明确的诊疗指南推荐。 ...

格隆汇12月23日丨众生药业(002317.SZ)公布，近日收到国家药品监督管理局核准签发的盐酸氨溴索口 服溶液《药品注册证书》。盐酸氨溴索是黏液溶解剂，能增加呼吸道黏膜浆液腺的分泌，减少黏液腺分 泌，从而降低痰液黏度；能促进肺表面活性物质的分泌，增加支气管纤毛运动，使痰液易于咳出。盐酸 氨溴索口服溶液适用于急、慢性支气管炎引起的痰液黏稠、咳痰困难，有明确的诊疗指南推荐。 ...

众生药业公告，近日收到国家药品监督管理局核准签发的盐酸氨溴索口服溶液《药品注册证书》。盐酸 氨溴索口服溶液为医保乙类药物，2022至2024年在中国公立医院及城市实体药店销售总额分别为7.11亿 元、8.18亿元、8.5亿元。此次获批标志着产品视同通过化学仿制药一致性评价，进一步丰富公司在呼吸 系统治疗领域的产品线。 ...

证券代码：002317 公告编号：2025-118 广东众生药业股份有限公司 关于获得盐酸氨溴索口服溶液《药品注册证书》的公告 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的盐酸氨溴索口服溶液《药品注册证书》。现将相关情况公告如 下： 一、药品注册证书主要信息 药品名称：盐酸氨溴索口服溶液 剂型：口服溶液剂 规格：10ml∶30mg、100ml∶0.3g 证书编号：2025S03794、2025S03795 药品批准文号：国药准字 H20256278、国药准字 H20256279 上市许可持有人：名称：广东众生药业股份有限公司，地址：广东省东莞市 石龙镇西湖工业区信息产业园 生产企业：名称：广东众生药业股份有限公司，地址：广东省东莞市石龙镇 西湖工业区信息产业园 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、产品简介 盐酸氨溴索是黏液溶解 ...

Group 1: Innovative Drug Development - The company focuses on independent research and development, integrating internal and external resources to address unmet clinical needs, particularly in metabolic and respiratory diseases [1] - As of now, two innovative drug projects have been approved for market, with several others in clinical trial stages [1] - ZSP1601, an innovative drug for treating metabolic dysfunction-related fatty liver disease (MASH), has shown significant efficacy in reducing liver inflammation markers in clinical trials [2] Group 2: Clinical Trials and Results - RAY1225 injection, a dual agonist for GLP-1 and GIP receptors, is currently undergoing multiple Phase III clinical trials for obesity and type 2 diabetes, with positive results reported in Phase II trials [2][12] - The company is advancing RAY1225's clinical trials for treating MASH, with the drug showing potential in improving liver conditions in animal models [13][15] - The company is also conducting Phase III trials for the innovative drug Anlavi (昂拉地韦) for treating influenza, with successful results in previous phases [3][5] Group 3: Market Access and Insurance Inclusion - Anlavi has been included in the 2025 National Medical Insurance Directory, enhancing patient access to this innovative treatment [7][9] - The company’s core products, including Lai Rui Te Wei (来瑞特韦) and other formulations, continue to be part of the updated medical insurance directory, ensuring broader patient coverage [9] Group 4: Future Directions and Research Focus - The company is exploring new drug development avenues in metabolic diseases, focusing on multi-target therapies and long-acting formulations [6] - There is a strategic emphasis on addressing unmet clinical needs in respiratory diseases, particularly with new antiviral agents targeting RSV [5][6]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | 2025-12-19 | 002317 | 众生药业 | 18.40 | 130.00 | 2,392.00大证券股份有限 | 华泰证券股份有限 | | | | | | | 公司东莞石龙证券 | 公司东莞国贸中心 | | | | | | | 营业部 | 证券营业部 | | 2025-12-19 | 002317 | 众生药业 | 18.40 | 130.00 | 2,392.00大证券股份有限 | 华泰证券股份有限 | | | | | | | 公司东莞石龙证券 | 公司东莞国贸中心 | | | | | | | 营业部 | 证券量不出 | 12月19日，众生药业大宗交易成交260万股，成交额4784万元，占当日总成交额的6.41%，成交价18.4 元，较市场收盘价19.17元折价4.02%。 ...

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced a decline of 2.02% on December 18, with significant trading activity and a notable year-to-date increase of 62.01% despite recent short-term declines [1][2]. Group 1: Stock Performance - As of December 18, Zhongsheng Pharmaceutical's stock price is 19.36 CNY per share, with a market capitalization of 16.455 billion CNY [1]. - The stock has seen a year-to-date increase of 62.01%, but has declined by 6.97% over the last five trading days, 16.84% over the last 20 days, and 3.68% over the last 60 days [1]. - The company has appeared on the trading leaderboard eight times this year, with the most recent appearance on November 28, where it recorded a net buy of -277 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhongsheng Pharmaceutical reported a revenue of 1.889 billion CNY, a year-on-year decrease of 1.01%, while the net profit attributable to shareholders increased by 68.40% to 251 million CNY [2]. - The company has distributed a total of 2.019 billion CNY in dividends since its A-share listing, with 502 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Zhongsheng Pharmaceutical is 72,900, a decrease of 18.90% from the previous period, with an average of 10,445 circulating shares per shareholder, an increase of 23.31% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 22.647 million shares, an increase of 13.474 million shares from the previous period [3].

证券代码：002317 公告编号：2025-117 广东众生药业股份有限公司 关于公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第八届董事会第二十次会议及于 2025 年 5 月 19 日召开的 2024 年年度股东大会 审议通过了《关于公司向合并报表范围内子公司提供担保额度的议案》，为统筹 安排子公司（指"公司合并报表范围内的子公司"，下同）的生产经营活动，确 保子公司的生产经营持续发展，提高资金使用效率，公司继续为子公司向银行申 请信贷业务提供合计不超过人民币 20 亿元额度的连带责任保证。授权董事长在 上述额度内根据具体情况实施相关事宜并签署有关文件。 具体内容详见公司于 2025 年 4 月 26 日及 2025 年 5 月 20 日刊载在《证券时 报》和巨潮资讯网（www.cninfo.com.cn）的相关公告。 近日，公司全资子公司广东众生医药贸易有限公司（以下简称"众生医贸"） 为满足日常生产经营的需要，降低融资 ...

（文章来源：证券日报） 证券日报网讯 12月16日，众生药业在互动平台回答投资者提问时表示，公司会充分结合实际，积极拥 抱新技术，探索新技术的无限可能。 ...

Core Insights - The report emphasizes the continuous improvement of the global competitiveness of Chinese innovative pharmaceutical companies, focusing on innovation from both "therapeutic areas" and "technology platforms" [5][6] - The growth of commercial health insurance premiums is expected to provide new payment sources for medical expenses, as the scale of commercial health insurance is projected to reach 977.4 billion yuan by 2024 [29][30] - The report identifies potential therapeutic areas such as metabolic diseases (e.g., weight loss), chronic diseases (e.g., hypertension, hyperlipidemia), and central nervous system diseases (e.g., Alzheimer's, Parkinson's) as key focus areas for innovation [5][38] - Emerging technology platforms like small nucleic acid drugs, radioactive drugs (RDC), and CAR-T therapies are highlighted as significant areas for investment [5][38] Market Review - As of November 15, 2025, the pharmaceutical sector has outperformed the market, with the pharmaceutical index rising by 22.09% compared to a 17.62% increase in the CSI 300 index, resulting in a 4.47 percentage point outperformance [11] - The chemical preparation sector showed the best performance, increasing by 40.52%, followed by medical services (+36.98%) and chemical raw materials (+25.34%) [20] - The overall PE valuation of the pharmaceutical sector is at 30.89 times, which is relatively low compared to historical averages, indicating potential for future growth [22][23] Innovative Drugs - The report notes that the growth of health expenditures in China, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating a robust market for innovative drugs [26][27] - The analysis of multinational corporations (MNCs) reveals that innovation is a core competitive advantage, with companies like Eli Lilly and Novartis showing significant growth driven by innovative products in advanced technology fields such as GLP-1 and ADC [31][32] - The report highlights the strong sales performance of GLP-1 drugs, with Eli Lilly's Mounjaro generating $6.515 billion in revenue in Q3 2025, reflecting a 109% year-on-year increase [44] CXO and Upstream - The report indicates a slight increase in pharmaceutical financing, with a recovery in business development transactions and H-share IPOs, which is expected to stimulate innovation [5] - The demand for external CXO services is growing, particularly in emerging fields such as peptides and small nucleic acids, while internal CXO orders are also showing signs of recovery [5][39] Medical Devices - The domestic medical device market is currently under pressure due to policy impacts, but improvements are anticipated as companies continue to innovate and expand internationally [5] - The report suggests that the industry fundamentals are expected to improve, with a focus on companies like Mindray Medical and Microelectrophysiology [5][39]